← BioTransfer GEO Dataset Finder
GEO series

Circular RNA circTNK2 contributes to immune evasion and acts as a nanotherapeutic target in tamoxifen-resistant ER-positive breast cancer

GSE282082 Homo sapiens (human) Non-coding RNA profiling 10 samples Submitted 2025/11/20 Platform GPL24676
At a glance

Non-coding RNA profiling · human · 10 samples

What it is
Non-coding RNA profilingLevels of RNAs that do not code for proteins, such as miRNA or lncRNA.
Organism
Homo sapiens (human)
Topic
Breast cancerThis series is part of our curated briefing on it.
Samples
10 samples: 3 × S vs 2 × oe_circIRESmut vs 2 × oe_circGroups are read from the sample names, not from the paper. Check the list below.
Data you can get
A processed table (series matrix) and supplementary files from NCBI; the raw sequencing reads from ENA. Which of these hold counts depends on the study, so check the file list.
Summary (written by the submitters)
circTNK2, a circular RNA, is significantly overexpressed in tamoxifen-resistant breast cancer tissues and is linked to poor prognosis. circTNK2 encodes a novel 487-amino acid protein, termed C-TNK2-487aa, which inhibits the recruitment of natural killer (NK) cells. Mechanistic studies reveal that C-TNK2-487aa interacts with STAT3 and promotes its phosphorylation in ER-positive breast cancer cells.
Read the full summary ↓
The increased phosphorylated STAT3 then competes with STAT1 binding, inhibiting the formation of STAT1 homodimers required for CXCL10 transcription, ultimately leading to immune evasion. Additionally, circTNK2 binds to SRSF1 and promotes tamoxifen resistance and breast cancer cell proliferation. Co-delivery of circTNK2 antisense oligonucleotides (ASO) and CXCL10 plasmid DNA mediated by BC-targeting ZIF-8 nanoparticles markedly suppresses breast cancer growth, reverses tamoxifen resistance, and increases tumor infiltration of CD56+ NK cells in vivo. These findings underscore the critical role of the circTNK2-encoded peptide in tamoxifen resistance and immune evasion, providing a therapeutic vulnerability in treating tamoxifen-resistant breast cancer.
This dataset
Download · which file do I need?

Direct links to NCBI and ENA, no account and no request form. Pick by what you want to do: take the small processed table to look, the supplementary files to re-analyse, or the original raw data to start over.

1 · Just have a look

Processed table

The series matrix: one table of values per sample as the submitters processed it. The smallest download, and it opens in Excel or R. Start here to see what the data look like.

2 · Re-analyse it

Supplementary files

The count tables and other files the authors uploaded. Take only the samples you need, or the whole study as GSE282082_RAW.tar (it can run to tens of gigabytes).

3 · Start from the raw reads

Raw sequencing reads

The original FASTQ files, straight from the sequencer, held at ENA. Large, and you align them yourself, so only choose this if you need to re-process the study from scratch.

Also filed as BioProject PRJNA1186974 and SRA study SRP545619. Searching any of these in the dataset finder brings you back here.

Study design
3 × S vs 2 × oe_circIRESmut vs 2 × oe_circ

Supports a between-group comparison across 7 samples.

How we read this: 3 replicated groups read from 10 sample titles; they account for 7 of them. These groups are guessed from the sample names, not taken from the paper, so check them against the sample list below before relying on them.

Samples in this study
More Breast cancer datasets

Search all human RNA-seq datasets in GEO →

Share this dataset

Metadata from NCBI GEO, cached and refreshed periodically — the NCBI page above is authoritative. Downloads link straight to NCBI/ENA; nothing is proxied through BioTransfer.